NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1.

加利福尼亚州纽波特海滩（商业新闻短讯）--Evolus，Inc.（纳斯达克代码：EOLS），一家专注于构建消费品牌美学组合的性能美容公司，今天宣布任命库珀公司总裁兼首席执行官阿尔伯特·G·怀特三世为Evolus董事会成员，自7月1日起生效。

Mr. White will also serve as a member of Evolus’ Compensation Committee..

怀特先生还将担任Evolus薪酬委员会的成员。。

“We are pleased to welcome Al White to the Evolus Board,” said Vik Malik, Chairman of the Board of Directors. “Al’s extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aesthetics company to a multi-product performance beauty innovator.

“我们很高兴欢迎Al White加入Evolus董事会，”董事会主席维克·马利克（VikMalik）表示。“随着Evolus从单一产品美学公司走向多产品性能美容创新者，Al丰富的领导经验、行业知识以及建立领先医疗技术公司的良好记录将成为宝贵的资源。

His expertise will help Evolus further its strategy and aid in our focus on delivering long-term shareholder value.”.

他的专业知识将有助于Evolus进一步推进其战略，并有助于我们专注于提供长期股东价值。”。

Mr. White commented, “I am honored to join the Evolus Board of Directors at such a pivotal moment in the company’s history. The company’s flagship product, Jeuveau®, together with its millennial consumer focus and direct-to-consumer digital strategy, is gaining significant traction in the medical aesthetics industry, and its pipeline of filler products will complement the neurotoxin offering.”.

怀特先生评论道：“我很荣幸在公司历史上如此关键的时刻加入Evolus董事会。公司的旗舰产品Jeuveau®，以及其千年消费者关注和直接面向消费者的数字战略，在医疗美容行业获得了显着的牵引力，其填充产品管道将补充神经毒素产品。”。

Mr. White has served as President & Chief Executive Officer of The Cooper Companies, Inc., branded CooperCompanies (NASDAQ: COO), a leading global medical device company in contact lenses, fertility, and women’s health, since May 2018. Previously, he served as Chief Financial Officer from November 2016 until his appointment as CEO and he also served as Executive Vice President and Chief Strategy Officer, positions he held from December 2015 and July 2011, respectively.

自2018年5月以来，怀特先生一直担任Cooper Companys，Inc.的总裁兼首席执行官，该公司是全球领先的隐形眼镜、生育和女性健康医疗器械公司CooperCompanys（纳斯达克股票代码：COO）。此前，他从2016年11月起担任首席财务官，直到被任命为首席执行官，并分别于2015年12月和2011年7月担任执行副总裁和首席战略官。

From August 2015 to May 2018, Mr. White also directed The Cooper Companies, Inc. women’s healthcare business and served as Chief Executive Officer of Cooper Medical Inc., the parent company to CooperSurgical. Previously, he served as Vice President, Investor Relations from November 2007 through March 2013 and as Vice President and Treasurer from April 2006 through December 2012.

2015年8月至2018年5月，怀特先生还领导了Cooper Companys，Inc.的女性保健业务，并担任CooperSurgical母公司Cooper Medical Inc.的首席执行官。此前，他曾于2007年11月至2013年3月担任投资者关系副总裁，并于2006年4月至2012年12月担任副总裁兼财务主管。

Prior to joining The Cooper Companies, Inc., Mr. White was a Director with KeyBanc Capital Markets for three years and held a number of leadership positions within KeyBank National Association over the prior eight years..

在加入Cooper Companys，Inc.之前，White先生曾在KeyBanc Capital Markets担任三年董事，并在过去八年中在KeyBank National Association担任过多个领导职位。。

Following these changes, Evolus’ Board of Directors will be composed of seven directors, six of whom are independent.

在这些变化之后，Evolus的董事会将由七名董事组成，其中六名是独立董事。

About Evolus, Inc.

关于Evolus，Inc。

Evolus (NASDAQ: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology.

Evolus（纳斯达克股票代码：EOLS）是一家全球性能美容公司，通过其独特的、以客户为中心的商业模式和创新的数字平台，为下一代美容消费者发展美学神经毒素市场。我们的使命是在我们的旗舰产品Jeuveau®（prabotulinumtoxinA-xvfs）的基础上，成为一家全球性的多产品美学公司，Jeuveau®是第一种也是唯一一种专门用于美学的神经毒素，并使用Hi Pure™技术在最先进的设施中制造。

Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on  LinkedIn, X, Instagram or Facebook..

Evolus正在扩大其产品组合，已签订最终协议，成为Evolysse™的美国独家经销商，以及Estyme®的欧洲独家经销商，Estyme®是一种目前处于后期开发阶段的独特真皮填充剂系列。请访问www.evolus.com，并在LinkedIn、X、Instagram或Facebook上关注我们。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate.

。

Any statements contained herein that are not statements of historical or current facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, or other comparable terms intended to identify statements about the future.

本文中包含的任何不是历史或当前事实陈述的陈述都是前瞻性陈述。在某些情况下，您可以通过诸如“预期”、“相信”、“可能”、“估计”、“预期”、“打算”、“可能”、“计划”、“潜力”、“预测”、“项目”、“应该”、“将会”、“将会”或这些术语的否定词，或其他旨在识别未来陈述的类似术语来识别前瞻性陈述。

The company’s forward-looking statements include, but are not limited to, statements related to anticipated product launches; market size, conditions and consumer demand; and the timing of regulatory submissions and approvals..

公司的前瞻性声明包括但不限于与预期产品发布相关的声明；市场规模、条件和消费者需求；以及监管提交和批准的时间安排。。

The forward-looking statements included herein are based on our current expectations, assumptions, estimates and projections, which we believe to be reasonable, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements.

本文中包含的前瞻性陈述基于我们目前的预期、假设、估计和预测，我们认为这些是合理的，并且存在可能导致实际结果与前瞻性陈述中明示或暗示的结果产生重大差异的风险和不确定性。

These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to, uncertainties associated with our ability to comply with the terms and conditions in the Medytox Settlement Agreements, our ability to fund our future operations or obtain financing to fund our operations, unfavorable global economic conditions and the impact on consumer discretionary spending, uncertainties related to customer and consumer adoption of Jeuveau® and Evolysse™, the efficiency and operability of our digital platform, competition and market dynamics, our ability to successfully launch and commercialize our products in new markets, including the Evolysse™ dermal filler product line in the U.S., our ability to maintain regulatory approvals of Jeuveau® or obtain regulatory approvals for new product candidates or indications, our reliance on Symatese to achieve regulatory approval for the Evolysse™ dermal filler product line in the U.S., and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled “Risk Factors” in our Annual Report on Form 10-K Form and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the Securities and Exchange Commission on May 7, 2024.

这些风险和不确定性，所有这些都难以或不可能准确预测，其中许多超出了我们的控制范围，包括但不限于与我们遵守Medytox和解协议条款和条件的能力相关的不确定性，我们为未来运营提供资金或获得资金为我们的运营提供资金的能力，不利的全球经济状况以及对消费者可自由支配支出的影响，与客户和消费者采用Jeuveau®和Evolyse™有关的不确定性，我们数字平台的效率和可操作性，竞争和市场动态，我们在新市场成功推出和商业化我们产品的能力，包括Evolyse™真皮填充产品线在美国的能力，我们保持监管批准的能力Jeuveau®或获得新产品候选产品或适应症的监管批准，我们依靠Symatese获得美国Evolysse™真皮填充产品线的监管批准，以及我们向美国证券交易委员会提交的文件中描述的其他风险，包括2024年5月7日提交给美国证券交易委员会的10-K表年度报告和10-Q表季度报告中题为“风险因素”的部分。

These filings can be accessed online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking state.

这些文件可以在www.sec.gov上在线访问。警告读者不要过度依赖这些前瞻性状态。

Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc.

Jeuveau®和Nuceiva®是Evolus，Inc.的注册商标，Evolysse™是Evolus，Inc.的商标。

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Hi Pure™是大宇制药有限公司的商标。

Estyme® is a trademark of Symatese Aesthetics S.A.S.

Estyme®是Symatese美学公司的商标。